Dow Jones

51 202,26

0,70%

DAX

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Veraxa Biotech Ag (VRXA)
Veraxa Biotech Ag (VRXA) Actualités

Veraxa Biotech Ag (VRXA)

20,00

-4,79

(-19,32%)

À la fermeture: 13 Juin 10:00PM

20,00

0,00

( 0,00% )

Après les heures de négociation: 12:28AM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the...

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the...

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies...

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

ZURICH, May 29, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed...

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

ZURICH, May 20, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel...

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

ZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and...

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug...

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

BROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced that holders of the units...

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

BROOKLYN, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) today announced that it closed its...

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

BROOKLYN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced today the pricing of its...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Muller Die Lila Logistik

USOTC

NHEL

Natural Health Farm (EM)

USOTC

AMTFF

AmeriTrust Financial Tec... (QB)

Ac Dly Rng Acc Nts Lkd U...

Zero Coupon Securities d...

Embention Sistemas Intel...

USOTC

GDNGY

Gudang Garam TBK PT (PK)

NYSE

NMG

Nouveau Monde Graphite

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Veraxa Biotech Ag (VRXA)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.